119-HR-8918 Journalist Public Summary

Public Summary — BIO-SCALE Act (H.R. 8918, 119th Congress)

A bipartisan-leaning proposal to close the “scale‑up gap” in U.S. bioindustrial manufacturing by funding open‑access pilot facilities that multiple companies and universities can use before going full commercial. [2]House.gov — Congressman Baird Introduces Bill to Accelerate Commercial Biotechn…

1) Headline Summary: Create a small national network of open‑access bioindustrial pilot plants so innovators can test and scale new bioprocesses before building full factories. [1]House.gov — BIO-SCALE Act — bill text PDF posted by Rep. Jim Baird

2) What It Does: The bill directs the Commerce Department (through EDA) to fund at least three regional, nonprofit, product‑agnostic facilities with fermentation and processing equipment (roughly 1,500–75,000‑liter scale). Awards would be made via a competitive process, coordinated with DOE and DoD programs, with a 180‑day implementation plan to Congress, facility selections within one year, reporting requirements, open‑access policies, and tailored IP rules (federal‑employee inventions enter the public domain; others keep IP under standard law). It authorizes $345M for FY2026–2028 and $117M for FY2029–2030 (total $462M), and sunsets the authority after 10 years. [1]House.gov — BIO-SCALE Act — bill text PDF posted by Rep. Jim Baird

3) Who’s For It:

• Lead sponsor: Rep. Jim Baird (R‑IN) says the bill removes roadblocks to getting biotech from lab to market and builds U.S. leadership. [2]House.gov — Congressman Baird Introduces Bill to Accelerate Commercial Biotechn…
• Policy community: The National Security Commission on Emerging Biotechnology has urged Congress to fund a national network of pre‑commercial bioindustrial facilities—an idea this bill mirrors. [3]U.S. Senate (NSCEB) — NSCEB Final Report (Executive Summary) — recommendations…
• Ecosystem stakeholders: Organizations like BioMADE emphasize bridging the lab‑to‑plant “valley of death” and expanding shared infrastructure and workforce—goals aligned with the bill’s approach. [4]Manufacturing USA — BioMADE institute overview

4) Who’s Against It (or potential concerns raised):

• Cost: Authorizes $462M through FY2030; fiscal hawks may question new federal spending. [1]House.gov — BIO-SCALE Act — bill text PDF posted by Rep. Jim Baird
• Overlap: Critics may ask whether new sites duplicate existing federal capabilities (e.g., DOE’s ABPDU) rather than complement them—though the bill instructs Commerce to coordinate and avoid redundancy. [5]U.S. Department of Energy — DOE article on ABPDU scale‑up facility
• Access and data/IP: The bill’s open‑access and data‑sharing model could raise questions about protecting proprietary know‑how; it sets basic guardrails (public‑domain rule for federal‑employee inventions; others retain IP). [1]House.gov — BIO-SCALE Act — bill text PDF posted by Rep. Jim Baird

5) What’s Next: As of May 23, 2026, H.R. 8918 has been introduced and referred to the House Committees on Transportation and Infrastructure and on Financial Services; it awaits any hearings or markups. [6]Quiver Quantitative — H.R. 8918 (119th): Bill summary and actions

Key numbers from the introduced bill: [1]House.gov — BIO-SCALE Act — bill text PDF posted by Rep. Jim Baird